Why is this study being conducted?
This research study is testing a new potential treatment for chronic heart failure. The new treatment is called tovinontrine. The main purpose of this research is to learn about the effects of the research medicine, tovinontrine, when compared to placebo, and to see how safe and effective tovinontrine is for patients with chronic heart failure.
Who is eligible to participate in this study?
You may be eligible if you:
- Are 18 years of age or older
- Have a diagnosis of clinical heart failure
- Are currently on a stable dose of medication for heart failure
Those who are interested in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be about 16 weeks and you will have about 8 trial visits.
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will be assigned randomly by chance (like the flip of a coin) to receive tovinontrine or placebo.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their travel associated with each study visit.
Contact Subaat Khan
To learn more about this clinical trial, please contact:
Subaat Khan, Clinical Trial Coordinator.
0481 277 676 clinicaltrialunit@griffith.edu.au
Ethics approval number for the Heart Failure Trial: Bellberry Limited 2024-04-513 / 2024-05-586, GU HREC 2024/909 / 2024/908
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials